Table 3. Comparison of expression of CD8, CD68 and CCL18 in subtypes of WHO classification.
| CD8 | CD68 | CCL18 | |||||||
| Negative | Positive | χ2/P | Negative | Positive | χ2/P | Negative | Positive | χ2/P | |
| Gender | |||||||||
| Female | 12 (24.5) | 37 (75.5) | 1.081/0.299 | 33 (67.3) | 16 (32.7) | 1.846/0.174 | 29 (59.2) | 20 (40.8) | 0.842/0.359 |
| Male | 17 (34.0) | 33 (66.0) | 27 (54.0) | 23 (46.0) | 25 (50.0) | 25 (50.0) | |||
| Myasthenia gravis | |||||||||
| No | 15 (28.8) | 37 (71.2) | 0.011/0.918 | 30 (57.7) | 22 (42.3) | 0.389/0.533 | 28 (53.8) | 24 (46.2) | 0.022/0.883 |
| Yes | 14 (29.8) | 33 (70.2) | 30 (63.8) | 17 (36.2) | 26 (55.3) | 21 (44.7) | |||
| WHO classification | |||||||||
| A-AB | 1 (4.5) | 21 (95.5) | 34.372/<0.001 | 20 (90.9) | 2 (9.1) | 3.270/<0.001 | 17 (77.3) | 5 (22.7) | 21.541/<0.001 |
| B1-B3 | 13 (21.7) | 47 (78.3) | 39 (65.0) | 21 (35.0) | 36 (60.0) | 24 (40.0) | |||
| C | 15 (88.2) | 2 (11.8) | 1 (5.9) | 16 (94.1) | 1 (5.9) | 16 (94.1) | |||
| Masaoka's stage | |||||||||
| I-II | 1 (1.7) | 59 (98.3) | 56.123/<0.001 | 54 (90.0) | 6 (10.0) | 55.118/<0.001 | 49 (81.7) | 11 (18.3) | 45.186/<0.001 |
| III-IV | 28 (71.8) | 11 (28.2) | 6 (15.4) | 33 (84.6) | 5 (12.8) | 34 (87.2) | |||
| Adjuvant radiotherapy | |||||||||
| No | 26 (32.5) | 54 (67.5) | 2.070/<0.150 | 47 (58.8) | 33 (41.3) | 0.601/0.438 | 42 (52.5) | 38 (47.5) | 0.703/0.402 |
| Yes | 3 (15.8) | 16 (84.2) | 13 (68.4) | 6 (31.6) | 12 (63.2) | 7 (36.8) | |||
| Adjuvant chemotherapy | |||||||||
| No | 28 (33.7) | 55 (66.3) | 3.655/0.056 | 48 (57.8) | 35 (42.2) | 1.656/0.198 | 42 (50.6) | 41 (49.4) | 3.220/0.073 |
| Yes | 1 (6.3) | 15 (93.8) | 12 (75.0) | 4 (25.0) | 12 (75.0) | 4 (25.0) | |||